Based on financial statement, the company has about 2Q cash left. Given the cost and time to complete the 2nd Phase III trial of Ampion, what would be the expected timing and what net effect would a secondary have? Depending on the size and interim data releases, it might present a good buying opportunity.
Bill... Zertane might well be the wild-card. I they can complete a Zertane deal in the next few months, they may not need a secondary. We'll see. The Ampion trial cost was only $2.5M (versus the initial $4M+ budgeted). Who knows what second trial would cost.
Didn't Ampio also already set up a secondary company to do some of the testing on at least some of the pipeline products. Agree that Zertane is a drug that AMPE mgmt does not really care about. It is cdetrtainly for sale. Would also think some sort of partnership deal for either Ampion or their eye drug could be in the works. Almost impossible to gt all three to the consumer stage w/o more money from somewhere.